Method for synthesizing chiral 3,5-disubstituted morpholine compounds and useful intermediates therefor
A diastereoselective method for preparing chiral 3,5-disubstituted morpholine compounds addresses the need for stereoselective synthesis of SMAC mimetics intermediates, improving pharmaceutical manufacturing quality and cost-effectiveness.
Patent Information
- Application Number
- JP2024532837
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-08
- Filing Date
- 2022-12-02
- Publication Date
- 2024-11-15
AI Technical Summary
There is a need for stereoselective synthetic methods to prepare intermediates for SMAC mimetics, which are crucial for the preparation of mitochondrial-derived caspase activators used in treating proliferative diseases like cancer, as existing methods lack stereoselectivity and are not suitable for pharmaceutical manufacturing.
A diastereoselective method is developed for preparing chiral 3,5-disubstituted morpholine compounds, including processes for forming pharmaceutically acceptable salts, solid forms, enantiomers, and solvates, using specific chemical reactions and purification techniques to achieve high diastereomeric ratios.
The method provides high-purity, stereoselective intermediates for SMAC mimetics, enhancing the quality and cost-effectiveness of pharmaceutical production by ensuring high diastereomeric purity and stability.
Smart Images

Figure 2024542756000037 
Figure 2024542756000038 
Figure 2024542756000039
Abstract
Description
[Technical field]
[0001] Provided herein are synthetic methods and intermediates for the preparation of chiral 3,5-disubstituted morpholine compounds that can be used in the preparation of compounds useful as mitochondrial-derived factor activator of caspases (SMAC) mimetics for the treatment of proliferative diseases such as cancer. [Background technology]
[0002] The link between abnormal protein phosphorylation and the cause or consequence of disease has been known for over 20 years, therefore making protein kinases a very important group of drug targets. (See Cohen, Nature, 1:309-315 (2002); Gaestel et al. Curr. Med. Chem. 14: 2214-223 (2007); Grimminger et al. Nat. Rev. Drug Disc. 9(12):956-970 (2010)). A variety of protein kinase inhibitors are in clinical use in the treatment of a variety of diseases, such as cancer and chronic inflammatory diseases, including rheumatoid arthritis and psoriasis (See Cohen, Eur. J. Biochem., 268:5001-5010 (2001); Protein Kinase Inhibitors for the Treatment of Disease: The Promise and the Problems, Handbook of Experimental Pharmacology, Springer Berlin Heidelberg, 167 (2005)).
[0003] Apoptosis is a tightly regulated process that plays a key role in cellular development and homeostasis in higher organisms, eliminating damaged or unwanted cells (Kerr, JF et al., Br J Cancer, 1972, 26, 239-257). Abnormalities in the apoptotic process are involved in many human diseases, including cancer, autoimmune diseases and inflammation (Nicholson, DW et al., Nature, 2000, 407, 810-816). In fact, anti-apoptosis is a hallmark of cancer (Hanahan, D. et al., cell 2000, 100, 57-70; Hanahan, D. et al., cell, 2011, 144, 646-674).
[0004] Apoptosis can be induced by exogenous stimulation of cell death receptors or by endogenous stimulation released by mitochondria within the cell (Elmore, S., ToxicolPathol, 2007, 35, 495-516). Inhibitor of apoptosis proteins (IAPs) are important negative regulators in the extrinsic and intrinsic apoptotic pathways. IAPs were first identified in baculoviruses and can inhibit apoptosis in infected cells (Birnbaum, MJ et al., J Virol, 1994, 68, 2521-2528). IAPs are characterized by the presence of baculovirus IAP repeat (BIR) domains. BIR domains are approximately 70-80 amino acids in length and contain a ZN-binding motif that can promote protein-protein interactions involved in IAP function (Yang, YL, Cell Res, 2000, 10, 169-177). The human IAP family includes eight proteins: neuronal IAP (BIRC1), cellular IAP1 (cIAP1, BIRC2), cellular IAP2 (cIAP2, BIRC3), X-linked IAP (XIAP, BIRC4), survivin (BIRC5), ubiquitin-binding BIR domain apollon (BIRC6), melanoma IAP (ML-IAP, BIRC7), and IAP-like protein 2 (BIRC8). Of these, cIAP1, cIAP2, and XIAP play a direct role in apoptosis regulation (Salvesen, GS et al., Nat Rev Mol Cell Bio, 2002, 3, 401-410).
[0005] cIAP1 and cIAP2 (cIAPs) inhibit caspase-8-dependent extrinsic apoptotic pathways, such as that induced by TNF-α, through their ubiquitin ligase activity (Derakhshan, A. et al., Clin Cancer Res, 2017, 23, 1379-1387). Upon binding of TNF-α to its receptor TNFR1, cIAPs and tumor necrosis factor receptor type 1 associated death domain (TRADD), receptor interacting serine / threonine kinase 1 (RIPK1) and TNF receptor associated factors (TRAFs) are recruited to form complex I, activating the classical nuclear factor kappa B (NF-κB) pathway, which is known to promote inflammation, proliferation and cell survival (Samuel T. et al., J Biol Chem, 2006, 281, 1080-1090; Vince JE et al., J Biol Chem, 2009, 284, 35906-35915; Wang C. et al., Nature, 2001, 412, 346-351).
[0006] XIAP is the only IAP protein that inhibits both the extrinsic and intrinsic apoptosis pathways through its BIR domain, which directly prevents caspase activation (Deveraux QL et al., Nature, 1997, 388, 300-304). The BIR2 domain and preceding linker region of XIAP associate with the IAP-binding motif (IBM) and active sites of caspase-3 and caspase-7, the executioner caspases shared by extrinsic and intrinsic apoptosis, and inhibit their function (Chai J. et al., Cell, 2001, 104, 769-780; Riedl SJ et al., Cell, 2001, 104, 791-800). XIAP binds to procaspase-9 via its BIR3 domain and inhibits the dimerization and subsequent activation of caspase-9, the key inducible caspase in the intrinsic pathway (Shiozaki EN et al., Mol Cell, 2003, 11, 519-527).
[0007] cIAP1, cIAP2 and XIAP proteins are widely expressed in various tumor types. Moreover, positive expression of cIAP and XIAP is associated with aggressive cancer and poor prognosis (Che X. et al., Urol Oncol, 2012, 30, 450-456; Yang C. et al., J Exp Clin Cancer Res, 2016, 35, 158). Furthermore, downregulation or depletion of these IAPs has been shown to restore sensitivity to extrinsic or intrinsic apoptotic stimuli (Gu H. et al., Aging (Albany NY), 2018, 10, 1597-1608). Taken together, targeting IAP proteins offers a potential antitumor strategy.
[0008] The second mitochondria-derived caspase activator (SMAC), also known as direct IAP-binding protein of low pI (DIABLO), is an endogenous antagonist of cIAP1, cIAP2 and XIAP that promotes apoptosis (Du C. et al., Cell, 2000, 102, 33-42; Verhagen AM et al., Cell, 2000, 102, 43-53). SMAC is normally sequestered in mitochondria and released into the cytosol when cells undergo apoptosis. In the cytosol, the N-terminal mitochondrial targeting sequence of SMAC is cleaved to expose a tetrapeptide (Ala-Val-Pro-Ile), which allows SMAC to interact with the BIR domain of IAPs (Chai J. et al., Nature, 2000, 406, 855-862). Binding of SMAC to the BIR3 domains of cIAP1 and cIAP2 stimulates their E3 ubiquitin ligase activity and induces their proteasomal degradation. Loss of cIAP proteins promotes the formation of complex II, which contains RIPK1, caspase-8 and Fas death domain-associated protein (FADD), and triggers TNF-α-mediated apoptosis (Dueber EC et al., Science, 2011, 334, 376-380). Dimerized SMAC binds to the BIR2 and BIR3 domains of XIAP and disrupts its interaction with caspase-3, caspase-7 and caspase-9, leading to caspase-dependent apoptosis (Micheau, O. et al., Cell, 2003, 114, 181-190; Chai J. et al., Cell, 2001, 104, 769-780; Liu Z. et al., Nature, 2000, 408, 1004-1008).
[0009] SMAC mimetics are small molecules that contain four amino acids that mimic the N-terminus of SMAC (Ala-Val-Pro-Ile). Like SMAC, SMAC mimetics bind to the BIR domain of IAPs and antagonize the function of IAPs to promote apoptosis in cancer cells (Chai J. et al., Cell, 2001, 104, 769-780; Dueber EC et al., Science, 2011, 334, 376-380; Liu Z. et al., Nature, 2000, 408, 1004-1008; Verhagen AM et al., Cell, 2000, 102, 43-53). Taken together, SMAC mimetics represent novel cancer therapeutic candidates.
[0010] PCT / CN2021 / 098123, filed June 3, 2021, teaches a group of compounds as SMAC mimetics and teaches that the R,R-3,5-dimethylmorpholine moiety is required in most of the SMAC mimetics in this application. However, no stereoselective synthetic method for preparing the R,R-3,5-dimethyl-morpholine intermediate useful for preparing SMAC mimetics is yet available in the art.
[0011] Dieter Enders et al., Synthesis, 1994(01), 66-72, reported a diastereorandom synthesis route for 3,5-dimethylmorpholine that yielded an equimolar mixture of (S,S)-bis(β-hydroxyisopropyl)amine and meso-bis(β-hydroxyisopropyl)amine as synthetic intermediates. G. Cignarella et al., Gazz. Chim. Ital., 1962, 92, 3-16, reported a diastereorandom synthesis route for 2,2'-(benzylazanediyl)bis(propan-1-ol), an oil with a boiling point of 133-135°C at 0.2 mm Hg, and 2,2'-(benzylazanediyl)bis(propan-1-ol). L. Fontanella et al., Il Farmaco, Ed. Sci., 1982, 37(6), 378-386, report another diastereorandom route to 2,2'-(benzylazanediyl)bis(propan-1-ol).
[0012] Therefore, for the purpose of controlling pharmaceutical manufacturing, especially the quality and cost of pharmaceuticals, there is a need to develop stereoselective synthetic methods for the preparation of intermediates useful in the preparation of certain SMAC mimetics. Citation or identification of any reference in this section should not be construed as an admission that such reference is prior art to the present application. [Prior art documents] [Non-patent literature]
[0013] [Non-Patent Document 1] Cohen, Nature, 1:309-315 (2002) [Non-Patent Document 2] Gaestel et al. Curr.Med.Chem.14: 2214-223 (2007) [Non-Patent Document 3] Grimminger et al. Nat. Rev. Drug Disc. 9(12):956-970 (2010) [Non-Patent Document 4] Cohen, Eur. J. Biochem., 268:5001-5010 (2001) [Non-Patent Document 5] Kerr, JF et al., Br J Cancer, 1972, 26, 239-257 [Non-Patent Document 6] Nicholson, DW et al., Nature, 2000, 407, 810-816 [Non-Patent Document 7] Hanahan, D. et al., cell 2000, 100, 57-70 [Non-Patent Document 8] Hanahan, D. et al., cell, 2011, 144, 646-674 [Non-Patent Document 9] Elmore, S., Toxicol Pathol, 2007, 35, 495-516 [Non-Patent Document 10] Birnbaum, MJ et al., J Virol, 1994, 68, 2521-2528 Summary of the Invention
[0014] The present specification relates to a compound of formula (VIII): [ka] Diastereoselective processes for the preparation of pharma- ceutically acceptable salts, solid forms, enantiomers, isotopologues and solvates thereof are provided; The method comprises reacting a compound of formula (VII) [ka] of, It involves contacting with hydrogen (H2) in a solvent in the presence of a catalyst. In the formula, R 1 and R 2 is as provided herein.
[0015] In one embodiment, the compound of formula (VII) is a compound of formula (VI) [ka] of, It is prepared by contacting with an acid.
[0016] In one embodiment, the compound of formula (VI) is a compound of formula (IV) [ka] and, Compound of formula (V) [ka] and a reducing agent.
[0017] In one embodiment, the mixture of a compound of formula (IV) and a compound of formula (V) is [ka] and, Compound of formula (III) [ka] The compound is prepared by contacting
[0018] In one embodiment, the compound of formula (II) is a compound of formula (I) [ka] of, It is prepared by contacting with PhCHO.
[0019] The present specification relates to a compound of formula (VI): [ka] Pharmaceutically acceptable salts, solid forms, enantiomers, isotopologues and solvates thereof are provided, In the formula, R 1 and R2 is as provided herein.
[0020] The present specification provides compound 6, which has the following structure and is named (2R,2'R)-2,2'-(benzylazanediyl)bis(propan-1-ol). [ka]
[0021] In one embodiment, compound 6 is in a crystalline form having an X-ray powder diffraction pattern comprising peaks at about 22.54°, 27.09°, and 27.30° 2θ.
[0022] The present specification provides processes and intermediates useful for the preparation of SMAC mimetics disclosed in PCT / CN2021 / 098123, filed June 3, 2021.
[0023] Embodiments of the present invention can be more fully understood by reference to the detailed description and examples that are intended to illustrate non-limiting embodiments. [Brief description of the drawings]
[0024] [Figure 1] The 1H nuclear magnetic resonance (NMR) spectrum of compound 2 is shown.
[0025] [Diagram 2] The 1H NMR spectrum of compound 6 is shown.
[0026] [Diagram 3] The 1H NMR spectrum of compound 7 is shown.
[0027] [Figure 4] The 1H NMR spectrum of compound 8 is shown.
[0028] [Diagram 5] 1 shows the X-ray powder diffraction (XRPD) pattern of compound 6.
[0029] [Figure 6] 1 shows a differential scanning calorimetry (DSC) thermogram of compound 6.
[0030] [Figure 7] 1 shows a thermogravimetric analysis (TGA) thermogram of compound 6. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0031] definition As used in this specification and the appended claims, the indefinite articles "a," "a kind," and "a kind of," as well as the definite article "said," include plural and singular referents unless the context clearly dictates otherwise.
[0032] As used herein, unless otherwise indicated, the terms "about" and "approximately" when used in connection with an amount or weight percentage of a component of a composition means an amount or weight percentage that would be recognized by one of ordinary skill in the art to provide an equivalent pharmacological effect as that obtained at the specified amount or weight percentage. In certain embodiments, the terms "about" and "approximately" when used in this context encompass an amount or weight percentage that is within 30%, within 20%, within 15%, within 10%, or within 5% of the specified amount or weight percentage.
[0033] As used herein, unless otherwise explained, the terms "about" and "approximately," when used in conjunction with a value or range of values provided to characterize a particular solid form, such as a particular temperature or temperature range, such as those describing melting, dehydration, desolvation, or glass transition temperatures, mass change, such as mass change as a function of temperature or humidity, solvent or water content, e.g., expressed by mass or percentage, or peak position in an analysis, e.g., by IR or Raman spectroscopy or XRPD, indicate that said value or range of values may deviate to an extent that would be considered reasonable by one of skill in the art while still being indicative of said solid form. Techniques used to characterize crystalline forms and amorphous solids include, but are not limited to, thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), single crystal X-ray diffraction, vibrational spectroscopy (e.g., infrared (IR) and Raman spectroscopy), solid-state and solution nuclear magnetic resonance (NMR) spectroscopy, optical microscopy, hot stage optical microscopy, scanning electron microscopy (SEM), electron crystallographic and quantitative analysis, particle size analysis (PSA), surface area analysis, solubility studies, and dissolution studies. In certain embodiments, the terms "about" and "approximately" as used in this context indicate that the indicated value or range of values may vary within 30%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1.5%, 1%, 0.5%, or 0.25% of the recited value or range of values. For example, in some embodiments, the values of the XRPD peak positions can vary by up to ±0.2° 2θ (or ±0.2 degrees 2θ) while still indicating a particular XRPD peak.
[0034] As used herein, unless otherwise specified, a crystalline compound that is "pure", i.e., substantially free of other crystalline or amorphous solids, contains less than about 10% by weight of one or more other crystalline or amorphous solids, less than about 5% by weight of one or more other crystalline or amorphous solids, less than about 3% by weight of one or more other crystalline or amorphous solids, or less than about 1% by weight of one or more other crystalline or amorphous solids.
[0035] As used herein, unless otherwise stated, a "substantially physically pure" solid form is substantially free of other solid forms. In certain embodiments, a substantially physically pure crystalline form contains less than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05%, or 0.01% by weight of one or more other solid forms. Detection of other solid forms can be achieved by any method apparent to one of skill in the art, including, but not limited to, diffraction analysis, thermal analysis, elemental combustion analysis, and / or spectroscopy.
[0036] As used herein, unless otherwise described, a "substantially chemically pure" solid form is substantially free of other compounds (i.e., chemical impurities). In certain embodiments, a substantially chemically pure solid form contains less than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05%, or 0.01% by weight of one or more other chemical compounds. Detection of other compounds can be achieved by any method apparent to one of skill in the art, including, but not limited to, chemical analysis methods such as mass spectrometry, spectroscopic analysis, thermal analysis, elemental combustion analysis, and / or chromatographic analysis.
[0037] As used herein, and unless otherwise stated, a compound, solid form, or composition that is "substantially free" of another compound, solid form, or composition means that in certain embodiments the compound, solid form, or composition contains less than about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.05%, or 0.01% by weight of another compound, solid form, or composition.
[0038] An "alkyl" group is a saturated, partially saturated, or unsaturated, straight or branched, acyclic hydrocarbon having 1 to 10 carbon atoms, typically 1 to 8 carbon atoms, or in some embodiments, 1 to 6, 1 to 4, or 2 to 6, or 2 to 4 carbon atoms. Representative alkyl groups include -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, and -n-hexyl, and saturated branched alkyls include -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, isopentyl, neopentyl, -tert-pentyl, -2-methylphenyl, -3-methylphenyl, -4-methylphenyl, 2,3-dimethylbutyl, and the like. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, allyl, -CH=CH(CH), -CH=C(CH), -C(CH)=CH, -C(CH)=CH, -C(CH)=CH(CH), -C(CHCH)=CH, -C≡CH, -C≡C(CH), -C≡C(CHCH), -CHC≡CH, -CHC≡C(CH), and -CHC≡C(CHCH). Alkyl groups can be substituted or unsubstituted. When alkyl groups described herein are referred to as "substituted," they may be substituted with any one or more substituents, such as those found in the exemplary compounds and embodiments disclosed herein, as well as halogen (chlorine, iodine, bromine, or fluorine), alkyl, hydroxyl, alkoxy, alkoxyalkyl, amino, alkylamino, carboxy, nitro, cyano, thiol, thioether, imine, imide, amidine, guanidine, enamine, aminocarbonyl, acylamino, phosphonate, phosphine, thiocarbonyl, sulfinyl, sulfone, sulfonamide, ketone, aldehyde, ester, urea, carbamate, oxime, hydroxylamine, alkoxyamine, aralkoxyamine, N-oxide, hydrazine, hydrazide, hydrazone, azide, isocyanate, isothiocyanate, cyanate, thiocyanate, B(OH)2, or O(alkyl)aminocarbonyl.
[0039] A "cycloalkyl" group is a saturated or partially saturated cyclic alkyl group having 3 to 10 carbon atoms, having a single ring or multiple fused or bridged rings, and optionally substituted with 1 to 3 alkyl groups. In some embodiments, the cycloalkyl group has 3 to 8 ring members, and in other embodiments, the number of ring carbon atoms ranges from 3 to 5, 3 to 6, or 3 to 7. Such cycloalkyl groups include, for example, monocyclic structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 1-methylcyclopropyl, 2-methylcyclopentyl, 2-methylcyclooctyl, and the like, or polycyclic or bridged ring structures such as 1-bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, adamantyl, and the like. Examples of unsaturated cycloalkyl groups include cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, and hexadienyl. The cycloalkyl groups may be substituted or unsubstituted. Examples of such substituted cycloalkyl groups include cyclohexanol and the like.
[0040] "Aryl" is a group, an aromatic carbocyclic group of 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl). In some embodiments, the aryl group has 6 to 14 carbon atoms, and in other embodiments, the ring portion of the aryl group contains 6 to 12, or even 6 to 10 carbon atoms. Specific aryl groups include phenyl, biphenyl, naphthyl, and the like. Aryl groups can be substituted or unsubstituted. The phrase "aryl group" also includes groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, and the like).
[0041] A "heteroaryl" group is an aryl ring system having 1-4 heteroatoms as ring atoms in the heteroaromatic ring system, with the remaining atoms being carbon atoms. In some embodiments, heteroaryl groups contain 3-6 ring atoms, and in other embodiments, 6-9 or even 6-10 atoms in the ring portion of the group. Suitable heteroatoms include oxygen, sulfur, and nitrogen. In certain embodiments, the heteroaryl ring system is monocyclic or bicyclic. Non-limiting examples include, but are not limited to, the following groups: For example, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, benzisoxazolyl (e.g., benzo[d]isoxazolyl), thiazolyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, benzothienyl, furanyl, benzofuranyl, indolyl (e.g., indolyl-2-onyl or isoindolin-1-onyl), azaindolyl (pyrrolopyridinyl or 1H-pyrrolo[2,3-b]pyridinyl), indazolyl, benzimidazolyl (e.g., 1H-benzo[d]imidazolyl), imidazopyridinyl. (e.g., azabenzimidazolyl or 1H-imidazo[4,5-b]pyridinyl), pyrazolopyridinyl, triazolopyridinyl, benzotriazolyl (e.g., 1H-benzo[d][1,2,3]triazolyl), benzoxazolyl (e.g., benzo[d]oxazolyl), benzothiazolyl, benzothiadiazolyl, isoxazolopyridinyl, thionaphthyl, purinyl, xanpurinyl, adenyl, guaninyl, quinolinyl, isoquinolinyl (e.g., 3,4-dihydroisoquinolin-1(2H)-onyl), tetrahydroquinolinyl, quinoxalinyl and quinazolinyl.
[0042] A "heterocyclyl group" is an aromatic (also called heteroaryl) or non-aromatic cycloalkyl in which one to four ring carbon atoms are independently replaced with a heteroatom from the group consisting of O, S, and N. In some embodiments, a heterocyclyl group contains 3 to 10 ring members, while other such groups have 3 to 5, 3 to 6, or 3 to 8 ring members. Heterocyclyl groups may also be attached to other groups at any ring atom (i.e., any carbon atom or heteroatom of the heterocycle). Heterocycloalkyl groups may be substituted or unsubstituted. Heterocyclyl groups include unsaturated, partially saturated, and saturated ring systems such as imidazolyl, imidazolinyl, and imidazolidinyl (e.g., imidazolidin-4-one or imidazolidin-2,4-dionyl). The term heterocyclyl group includes fused ring species including those containing fused aromatic and non-aromatic groups such as 1-aminotetralin and 2-aminotetralin, benzotriazolyl (e.g., 1H-benzo[d][1,2,3]triazolyl), benzimidazolyl (e.g., 1H-benzo[d]imidazolyl), 2,3-dihydrobenzo[1,4]dioxinyl, and benzo[1,3]dioxolyl. The term also includes bridged polycyclic ring systems containing heteroatoms, including, but not limited to, quinuclidinyl. Representative examples of heterocyclyl include aziridinyl, azetidinyl, azepanyl, oxetanyl, pyrrolidinyl, imidazolidinyl (e.g., imidazolidin-4-onyl or imidazolidin-2,4-dionyl), pyrazolidinyl, thiazolidinyl, tetrahydrothienyl, tetrahydrofuranyl, dioxolyl, furanyl, thienyl, pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, benzoisoxazolyl (e.g., benzo[d]isoxazolyl), thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, piperidinyl, piperazinyl (e.g., piperazin-2-onyl), morpholine, linyl, thiomorpholinyl, tetrahydropyranyl (e.g., tetrahydro-2H-pyranyl), tetrahydrothiopyranyl, oxathiolanyl, dioxyl, dithianyl, pyranyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, dihydropyridinyl, dihydrodithienyl, dihydrodithionyl, 1,4-dioxaspiro[4.5]decyl, homopiperazinyl, quinuclidinyl, indolyl (e.g., indolyl-2-onyl or isoindolin-1-onyl), indolinyl, isoindolyl , isoindolinyl, azaindolyl (pyrrolopyridinyl or 1H-pyrrolo[2,3-b]pyridinyl), indazolyl, indolizinyl, benzotriazolyl (e.g., 1H-benzo[d][1,2,3]triazolyl), benzimidazolyl (e.g., 1H-benzo[d]imidazolyl or 1H-benzo[d]imidazol-2(3H)-onyl), benzofuranyl, benzothienyl, benzothiazolyl, benzoxadiazolyl, benzoxazinyl, benzodithienyl, benzoxathiolanyl, benzothiaziny benzo[d]oxazolyl, benzoxazolyl (i.e., benzo[d]oxazolyl), benzothiazolyl, benzothiadiazolyl, benzo[1,3]dioxolyl, pyrazolopyridinyl (e.g., 1H-pyrazolo[3,4-b]pyridinyl, 1H-pyrazolo[4,3-b]pyridinyl), imidazopyridinyl (e.g., azabenzimidazolyl or 1H-imidazo[4,5-b]pyridinyl), triazolopyridinyl, isoxazolopyridinyl, purinyl, xanthaprinyl, adenyl, guaninyl, quinolinyl, isoquinolinyl (e.g., 3,Representative non-aromatic heterocyclyl groups include, but are not limited to, 4-dihydroisoquinolin-1(2H)-onyl), quinolidinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl, pteridinyl, thionaphthyl, dihydrobenzothiazinyl, dihydrobenzofuranyl, dihydroindolyl, dihydrobenzodithienyl, tetrahydroindolyl, tetrahydroindazolyl, tetrahydrobenzimidazolyl, tetrahydrobenzotriazolyl, tetrahydropyrrolopyridinyl, tetrahydropyrazolopyridinyl, tetrahydroimidazopyridinyl, tetrahydrotriazolopyridinyl, tetrahydropyrimidin-2(1H)-one, and tetrahydroquinolinyl. Representative non-aromatic heterocyclyl groups do not include fused ring species that contain fused aromatic groups. Examples of non-aromatic heterocyclyl groups include aziridinyl, azetidinyl, azepanyl, pyrrolidinyl, imidazolidinyl (e.g., imidazolidin-4-onyl or imidazolidin-2,4-dionyl), pyrazolidinyl, thiazolidinyl, tetrahydrothienyl, tetrahydrofuranyl, piperidinyl, piperazinyl (e.g., piperazin-2-onyl), morpholinyl, thiomorpholinyl, tetrahydropyranyl (e.g., tetrahydro-2H-pyranyl), tetrahydrothiopyranyl, oxathiolanyl, dithianyl, 1,4-dioxaspiro[4.5]decanyl, homopiperazinyl, quinuclidinyl, or tetrahydropyrimidin-2(1H)-one. Representative substituted heterocyclyl groups may be mono-substituted or substituted one or more times, such as, but not limited to, pyridyl or morpholinyl, and may be di-substituted, tri-substituted, tetra-substituted, pentad or hexad substituted, or di-substituted with a variety of substituents, such as those listed below.
[0043] A "cycloalkylalkyl" group is a group of the formula: -alkyl-cycloalkyl, where alkyl and cycloalkyl are as defined above. Substituted cycloalkylalkyl groups may be substituted on the alkyl, cycloalkyl, or both the alkyl and cycloalkyl portions of the group. Representative cycloalkylalkyl groups include, but are not limited to, methylcyclopropyl, methylcyclobutyl, methylcyclopentyl, methylcyclohexyl, ethylcyclopropyl, ethylcyclobutyl, ethylcyclopentyl, ethylcyclohexyl, propylcyclopentyl, propylcyclohexyl, and the like.
[0044] An "aralkyl" group is a group of the formula: -alkyl-aryl, where alkyl and aryl are as defined above. Substituted aralkyl groups may be substituted on the alkyl, aryl, or both the alkyl and aryl portions of the group. Representative aralkyl groups include, but are not limited to, benzyl and phenethyl, and fused (cycloalkylaryl)alkyl groups such as 4-ethyl-indanyl.
[0045] A "heterocyclylalkyl" group is a group of the formula: -alkyl-heterocyclyl, where alkyl and heterocyclyl are as defined above. Substituted heterocyclylalkyl groups may be substituted at the alkyl, heterocyclyl, or both the alkyl and heterocyclyl portions of the group. Representative heterocyclylalkyl groups include, but are not limited to, 4-ethyl-morpholinyl, 4-propylmorpholinyl, furan-2-ylmethyl, furan-3-ylmethyl, pyridin-3-ylmethyl, tetrahydrofuran-2-ylethyl, and indol-2-ylpropyl. When groups described herein (except alkyl groups) are referred to as "substituted", they may be substituted with any suitable one or more substituents. Illustrative examples of substituents include those found in the exemplary compounds and embodiments disclosed herein, as well as halogen (chlorine, iodine, bromine, or fluorine), alkyl, hydroxyl, alkoxy, alkoxyalkyl, amine, alkylamine, carboxyl, nitro, cyano, thiol, thioether, imine, imide, amidine, guanidine, enamine, aminocarbonyl, acylamino, phosphonate, phosphine, thiocarbonyl, sulfinyl, sulfone, sulfonamide, ketone, aldehyde, ester, urea, carbamate, oxime, hydroxylamine, alkoxyamine, aralkoxyamine, N-oxide, hydrazine, hydrazide, hydrazone, azide, isocyanate, isothiocyanate, cyanate, thiocyanate, oxygen ( [ka] ), B(OH)2, O(alkyl)aminocarbonyl, a cycloalkyl group which may be a single ring or multiple rings, fused or non-fused (e.g., cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), or a heterocyclic group which may be a single ring or multiple rings, fused or non-fused (e.g., pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or thiazinyl), a single ring or multiple rings, fused or non-fused aryl or heteroaryl. (e.g., phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridinyl, quinolinyl, isoquinolinyl, acridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzimidazolyl, benzothienyl or benzofuranyl), aryloxy, aralkoxy, heterocyclyloxy, and heterocyclylalkoxy.
[0046] "Halogen" is chlorine, iodine, bromine or fluorine.
[0047] A "hydroxyalkyl" group is an alkyl group as described above that is substituted with one or more hydroxy groups.
[0048] An "alkoxy" group is an --O-(alkyl), where alkyl is as defined above.
[0049] An "alkoxyalkyl" group is an -(alkyl)-O-(alkyl), where alkyl is defined above.
[0050] An "amine" group is a group of the formula: --NH.
[0051] A “hydroxylamine” group has the formula: # )OH or -NHOH, where R # is a substituted or unsubstituted alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, or heterocyclylalkyl, as defined herein.
[0052] An "alkoxyamine" group has the formula: # )O-alkyl or -NHO-alkyl groups, where R # is as defined above.
[0053] An "aralkoxyamine" group has the formula: # ) O-aryl or -NHO-aryl, where R # is as defined above.
[0054] An "alkylamine" group is a group of the formula: -NH-alkyl or -N(alkyl)2, where each alkyl is independently as defined above.
[0055] An "aminocarbonyl" group has the formula: -C(=O)N(R # )2, -C(=O)NH(R # ) or —C(═O)NH, where each R # is as defined above.
[0056] An "acylamino" group has the formula: -NHC(=O)(R # ) or -N(alkyl)C(=O)(R # ), where each alkyl and R # are independently as defined above.
[0057] An "O(alkyl)aminocarbonyl" group is a group of the formula: -O(alkyl)C(=O)N(R # )2, -O(alkyl)C(=O)NH(R # ) or -O(alkyl)C(=O)NH2, where each R # are independently as defined above.
[0058] An "N-oxide" group is a group of the formula: + -O - is the basis.
[0059] A "carboxy" group is a radical of the formula: --C(.dbd.O)OH.
[0060] A "ketone" group has the formula: # ), where R # is as defined above.
[0061] An "aldehyde" group is a radical of the formula: --CH(.dbd.O).
[0062] An "ester" group is a group represented by the formula: -C(=O)O(R # ) or -OC(=O)(R # ), where R # is as defined above.
[0063] A "urea" group has the formula: -N(alkyl)C(=O)N(R # )2, N(alkyl)C(=O)NH(R # ), -N(alkyl)C(=O)NH2, -NHC(=O)N(R # )2, -NHC(=O)NH(R # ) or -NHC(=O)NH2 # where each alkyl and R # are independently as defined above.
[0064] An "imine" group has the formula: -N=C(R # )2 or -C(R # )=N(R # ), where each R # are independently as defined above.
[0065] An "imido" group has the formula: -C(=O)N(R#)C(=O)(R # ) or -N((C=O)(R # ))2 groups, where each R # are independently as defined above.
[0066] A "carbamate" group has the formula: -OC(=O)N(R # )2, -OC(=O)NH(R #), -N(R # )C(=O)O(R # ) or -NHC(=O)O(R # ), where each R # are independently as defined above.
[0067] An "amidine" group has the formula: -C(=N(R # ))N(R # )2, -C(=N(R # ))NH(R # ), -C(=N(R # ))NH2, -C(=NH)N(R # )2, -C(=NH)NH(R # ), -C(=NH)NH2, -N=C(R # )N(R # )2, -N=C(R # )NH(R # ), -N=C(R # )NH2, -N(R # )C(R # )=N(R # ), -NHC(R # )=N(R # ), -N(R # )C(R # )=NH or -NHC(R # )=NH, where each R # are independently as defined above.
[0068] A “guanidine” group has the formula: —N(R # )C(=N(R # ))N(R # )2, -NHC(=N(R # ))N(R # )2, -N(R # )C(=NH)N(R # )2, -N(R # )C(=N(R # ))NH(R # ), -N(R # )C(=N(R # ))NH2, -NHC(=NH)N(R # )2, -NHC(=N(R # ))NH(R #), -NHC(=N(R # ))NH2, -NHC(=NH)NH(R # ), -NHC(=NH)NH2, -N=C(N(R # )2)2, -N=C(NH(R # ))2 or -N=C(NH2)2, where each R # are independently as defined above.
[0069] An "enamine" group has the formula: # )C(R # )=C(R # )2, -NHC(R # )=C(R # )2, -C(N(R # )2)=C(R # )2, -C(NH(R # ))=C(R # )2, -C(NH2)=C(R # )2, -C(R # )=C(R # )(N(R # )2), -C(R # )=C(R # )(NH(R # )) or -C(R # )=C(R # )(NH2), where each R # are independently as defined above.
[0070] An "oxime" group has the formula: -C(=NO(R # ))(R # ), -C(=NOH)(R # ), -CH(=NO(R # ) or —CH(═NOH), where each R # are independently as defined above.
[0071] A "hydrazide" group has the formula: -C(=O)N(R # )N(R # )2, -C(=O)NHN(R # )2, -C(=O)N(R # )NH(R # ), -C(=O)N(R# )NH2, -C(=O)NHNH(R # )2 or -C(=O)NHNH2, where each R # are independently as defined above.
[0072] A “hydrazine” group has the formula: # )N(R # )2, -NHN(R # )2, -N(R # )NH(R # ), -N(R # )NH2, -NHNH(R # )2 or -NHNH2, where each R # are independently as defined above.
[0073] A "hydrazone" group has the formula: -C(=NN(R # )2)(R # )2, -C(=N-NH(R # ))(R # )2, -C(=N-NH2)(R # )2, -N(R # )(N=C(R # )2) or -NH(N=C(R # )2), where each R # are independently as defined above.
[0074] An "azido" group is a radical of the formula: -N3.
[0075] An "isocyanate" group is a group of the formula: --N.dbd.C.dbd.O.
[0076] An "isothiocyanate" group is a group of the formula: --N.dbd.C.dbd.S.
[0077] A "cyanate" group is a group of the formula: -OCN.
[0078] A "thiocyanate" group is a group of the formula: -SCN.
[0079] A "thioether" group has the formula: -S(R #), where R # is as defined above.
[0080] A "thiocarbonyl" group has the formula: -C(=S)(R # ), where R # is as defined above.
[0081] A "sulfinyl" group has the formula: -S(=O)(R # ), where R # is as defined above.
[0082] A "sulfone" group has the formula: -S(=O)2(R # ), where R # is as defined above.
[0083] A "sulfonylamino" group has the formula: -NHSO(R # ) or -N(alkyl)SO2(R # ), where each alkyl and R # is as defined above.
[0084] A "sulfonamide" group has the formula: -S(=O)N(R # )2 or -S(=O)2NH(R # ) or -S(=O)2NH2, where each R # are independently as defined above.
[0085] A "phosphonate" group has the formula: -P(=O)(O(R # ))2, -P(=O)(OH)2, -OP(=O)(O(R # ))(R # ) or -OP(=O)(OH)(R # ), where each R # are independently as defined above.
[0086] A “phosphine” group has the formula: # )2 groups, where each R #are independently as defined above.
[0087] "Tautomers" refer to isomeric forms of a compound that are in equilibrium with each other. The concentration of isomeric forms can vary depending on the environment in which the compound is placed, for example, whether the compound is a solid or in an organic or aqueous solution. For example, in an aqueous solution, pyrazole can exhibit the following isomeric forms, called tautomers of each other: [ka]
[0088] As will be readily understood by one of ordinary skill in the art, various functional groups and other structures may exhibit tautomerism, and all tautomers of compound 6 are within the scope of the present invention.
[0089] The term "composition," as used herein, unless otherwise specified, is intended to include a product containing one or more specified ingredients (where indicated, in one or more specified amounts), and any product resulting directly or indirectly from the combination of one or more specified amounts of one or more specified ingredients. "Pharmaceutically acceptable" means that a diluent, excipient or carrier in a formulation must be compatible with the other ingredient or ingredients of the formulation and not deleterious to the recipient.
[0090] The term "solid form" refers to a physical form that is not in a liquid or gaseous state. As used herein, unless otherwise stated, the term "solid form" as used herein with respect to compound 6 refers to a physical form that includes compound 6 that is not in a liquid or gaseous state. A solid form may be a crystalline form or a mixture thereof. In certain embodiments, a solid form may be a liquid crystal. In certain embodiments, the term "solid form that includes compound 6" includes a crystalline form that includes compound 6. In certain embodiments, the solid form of compound 6 is form A, an amorphous solid, or a mixture thereof.
[0091] As used herein, unless otherwise stated, when the term "crystalline" is used to describe a compound, substance, modification, material, component, or product, it means that said compound, substance, modification, material, component, or product is substantially crystalline as determined by X-ray diffraction, unless otherwise stated.See, for example, Remington: The Science and Practice of Pharmacy, 21st Edition, Lippincott, Williams and Wilkins, Baltimore, MD (2005); The United States Pharmacopeia, 23rd Edition, 1843-1844 (1995).
[0092] The term "crystalline form" or "crystalline form" refers to a solid form of a crystal. In certain embodiments, a crystalline form of a substance may be substantially free of amorphous solids and / or other crystalline forms. In certain embodiments, a crystalline form of a substance may contain less than about 1% by weight, less than about 2% by weight, less than about 3% by weight, less than about 4% by weight, less than about 5% by weight, less than about 6% by weight, less than about 7% by weight, less than about 8% by weight, less than about 9% by weight, less than about 10% by weight, less than about 15% by weight, less than about 20% by weight, less than about 25% by weight, less than about 30% by weight, less than about 35% by weight, less than about 40% by weight, less than about 45% by weight, or less than about 50% by weight of one or more amorphous solids and / or other crystalline forms. In certain embodiments, a crystalline form of a substance may be physically and / or chemically pure. In certain embodiments, a crystalline form of a substance may be about 99%, about 98%, about 97%, about 96%, about 95%, about 94%, about 93%, about 92%, about 91%, or about 90% physically and / or chemically pure.
[0093] The term "amorphous" or "amorphous solid" means that the substance, component or product being referred to is substantially amorphous as determined by X-ray diffraction, unless otherwise stated. In particular, the term "amorphous solid" refers to a disordered solid form, i.e., a solid form in which the crystals lack long-range order. In certain embodiments, the amorphous solid of a substance may be substantially free of other amorphous solids and / or crystalline forms. In certain embodiments, the amorphous solid of a substance may contain less than about 1% by weight, less than about 2% by weight, less than about 3% by weight, less than about 4% by weight, less than about 5% by weight, less than about 10% by weight, less than about 15% by weight, less than about 20% by weight, less than about 25% by weight, less than about 30% by weight, less than about 35% by weight, less than about 40% by weight, less than about 45% by weight, or less than about 50% by weight of one or more other amorphous solids and / or crystalline forms. In certain embodiments, the amorphous solid of a substance may be physically and / or chemically pure. In certain embodiments, the amorphous solid of the material may be about 99%, about 98%, about 97%, about 96%, about 95%, about 94%, about 93%, about 92%, about 91%, or about 90% physically and / or chemically pure.
[0094] The term "diastereomeric ratio" or "dr" refers to the ratio of the mole percent of one diastereomer to the mole percent of the other diastereomer in a mixture.
[0095] The terms "solvate" and "solvated" as used herein refer to a solid form of a substance that contains a solvent, unless otherwise stated. The terms "hydrate" and "hydrate" refer to a solvate in which the solvent is water. A "polymorph of a solvate" means that a particular solvate composition exists in more than one solid form. Similarly, a "polymorph of a hydrate" means that a particular hydrate composition exists in more than one solid form. The term "desolvate" as used herein refers to a solid form of a substance that can be made by removing the solvent from a solvate. The terms "solvate" and "solvated" as used herein may refer to a solvate of a salt, co-crystal, or molecular complex. The terms "hydrate" and "hydrate" as used herein may refer to a hydrate of a salt, co-crystal, or molecular complex.
[0096] The term "one or more pharma-ceutically acceptable salts" as used herein refers to salts prepared from pharma-ceutically acceptable non-toxic acids or bases, including inorganic and organic acids and bases. Suitable pharma-ceutically acceptable salts include, but are not limited to, salts that, within the scope of sound medical judgment, are free of undue toxicity, irritation, allergic reactions, and the like, are suitable for use in contact with the tissues of humans and lower animals, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts can be prepared in situ during the final isolation and purification of the compounds disclosed herein, or separately by reacting a free base function with a suitable organic acid, or by reacting an acidic group with a suitable base.
[0097] It should also be noted that the compounds may contain unnatural proportions of atomic isotopes at one or more atoms. For example, the compounds may contain tritium ( 3 H), iodine-125( 125 I), Sulfur-35( 35 S) or carbon-14 ( 14 C) or may be radiolabeled with deuterium ( 2 H), Carbon-13( 13 C) or nitrogen-15(15 An "isotopologue" as used herein is an isotope-enriched compound. The term "isotopically enriched" means that an atom has an isotopic composition other than the natural isotopic composition of said atom. "Isotopically enriched" may refer to a compound in which at least one atom contained therein has an isotopic composition different from the natural isotopic composition of said atom. The term "isotopic composition" refers to the amount of each isotope present in a given atom. Radiolabeled and isotopically enriched compounds are useful as therapeutic agents (e.g., cancer and inflammation therapeutic agents), research reagents (e.g., binding assay reagents), and diagnostic agents (e.g., in vivo imaging agents). All isotopic variants of the compounds described herein (whether radioactive or not) are intended to be encompassed within the scope of the embodiments provided herein. In some embodiments, an isotopologue of a compound is provided, for example, an isotopologue is a deuterium, carbon-13, or nitrogen-15 enriched compound.
[0098] Additionally, if the stereochemistry of a structure or portion of a structure is not indicated, for example, with bold or dashed lines, said structure or portion of said structure is to be interpreted as encompassing all stereoisomers of it. Preparation method
[0099] The present specification provides processes and intermediates useful for the preparation of SMAC mimetics disclosed in PCT / CN2021 / 098123, filed June 3, 2021.
[0100] By way of example and not limitation, compounds of formula (VIII) may be prepared as outlined in Procedure 1 below and in the Examples described herein. [ka]
[0101] The present specification relates to a compound of formula (VIII): [ka] or a pharma- ceutically acceptable salt, solid form, enantiomer, isotope or solvate thereof; The method comprises reacting a compound of formula (VII) [ka] of, It involves contacting with hydrogen (H2) in a suitable solvent in the presence of a catalyst.
[0102] In some embodiments, R 1 and R 2 are independently unsubstituted or substituted C 1-5 In some embodiments, R 1 and R 2 are independently unsubstituted or substituted linear C 1-5 In some embodiments, R 1 and R 2 are independently unsubstituted or substituted branched C 1-5 In some embodiments, R 1 and R 2 are independently unsubstituted linear C 1-5 In some embodiments, R 1 and R 2 are independently unsubstituted branched C 1-5 It is an alkyl.
[0103] In some embodiments, R 1 and R 2 are independently unsubstituted or substituted C 1-4 In some embodiments, R 1 and R 2 are independently unsubstituted or substituted linear C 1-4 In some embodiments, R 1 and R 2 are independently unsubstituted or substituted branched C 1-4 In some embodiments, R1 and R 2 are independently unsubstituted linear C 1-5 In some embodiments, R 1 and R 2 are independently unsubstituted branched C 1-4 It is an alkyl.
[0104] In some embodiments, R 1 and R 2 are independently unsubstituted or substituted C 1-3 In some embodiments, R 1 and R 2 are independently unsubstituted or substituted linear C 1-3 In some embodiments, R 1 and R 2 are independently unsubstituted or substituted branched C 1-3 In some embodiments, R 1 and R 2 are independently unsubstituted linear C 1-3 In some embodiments, R 1 and R 2 are independently unsubstituted branched C 1-3 It is an alkyl.
[0105] In some embodiments, R 1 and R 2 are independently unsubstituted or substituted C 1-2 In some embodiments, R 1 and R 2 are independently unsubstituted C 1-2 In some embodiments, R 1 and R 2 are independently substituted C 1-2 It is an alkyl.
[0106] In some embodiments, R 1 and R 2are independently unsubstituted or substituted C 1-2 In some embodiments, R 1 and R 2 are independently unsubstituted C 1-2 In some embodiments, R 1 and R 2 are independently substituted C 1-2 It is an alkyl.
[0107] In some embodiments, R 1 and R 2 is independently an unsubstituted or substituted methyl group. In some embodiments, R 1 and R 2 are independently a substituted methyl group.
[0108] In some embodiments, R 1 and R 2 is an unsubstituted methyl group.
[0109] In one embodiment, the solvent is methanol, ethanol or isopropanol.
[0110] In one embodiment, the catalyst is Pd(OH)2 / C or Pd / C.
[0111] In one embodiment, the contacting occurs at a temperature of from about 25°C to about 55°C.
[0112] In one embodiment, the pressure of hydrogen (H2) is about 1 to about 10 atm. In one embodiment, the pressure of hydrogen (H2) is about 1 to about 5 atm. In one embodiment, the pressure of hydrogen (H2) is about 1 to about 3 atm. In one embodiment, the pressure of hydrogen (H2) is about 1 atm.
[0113] In one embodiment, the compound of formula (VII) is a compound of formula (VI) [ka] of, It is prepared by contacting with an acid.
[0114] In one embodiment, the acid is TfOH (trifluoromethanesulfonic acid).
[0115] In one embodiment, the contacting occurs at a temperature of about 0° C. to about 160° C. In one embodiment, the contacting occurs at a temperature of about 20° C. to about 140° C. In one embodiment, the contacting occurs at a temperature of about 40° C. to about 120° C. In one embodiment, the contacting occurs at a temperature of about 50° C. to about 100° C. In one embodiment, the contacting occurs at a temperature of about 70° C. to about 90° C. In one embodiment, the contacting occurs at a temperature of about 80° C. In one embodiment, the compound of formula (VI) is a compound of formula (IV) [ka] and, Compound of formula (V) [ka] and a reducing agent.
[0116] In one embodiment, the reducing agent is NaBH4, and the contacting is carried out in a solvent selected from the group consisting of methanol, ethanol, isopropanol, and mixtures thereof, at a temperature between about 15°C and about 35°C.
[0117] In one embodiment, R 1 and R 2 is a methyl group, and the compound of formula (VI) is in solid form at about 25°C.
[0118] In one embodiment, the compound of formula (VI) is in crystalline form at about 25°C.
[0119] In one embodiment, the melting point temperature of the compound of formula (VI) is from about 91°C to about 93°C.
[0120] In one embodiment, the mixture of a compound of formula (IV) and a compound of formula (V) is [ka] and, Compound of formula (III) [ka] The compound is prepared by contacting
[0121] In one embodiment, the contacting is performed in the presence of a suitable base and in a suitable solvent. In one embodiment, the base is 2,6-lutidine. In one embodiment, the solvent is dichloromethane. In one embodiment, the contacting is performed at about -10°C to about 50°C. In one embodiment, the contacting is performed at about 0°C to about 40°C. In one embodiment, the contacting is performed at about 5°C to about 20°C.
[0122] In one embodiment, the compound of formula (II) is a compound of formula (I) [ka] of, It is prepared by contacting with PhCHO.
[0123] In one embodiment, the contacting is performed in the presence of a suitable base and in a suitable solvent. In one embodiment, the base is NaHCO3. In one embodiment, the solvent is methanol. In one embodiment, the contacting is performed at a temperature between about 0°C and about 120°C. In one embodiment, the contacting is performed at a temperature between about 20°C and about 100°C. In one embodiment, the contacting is performed at a temperature between about 40°C and about 80°C. In one embodiment, the contacting is performed at a temperature of about 62°C. compound
[0124] The present specification relates to a compound of formula (VI): [ka]
[0125] Pharmaceutically acceptable salts, solid forms, enantiomers, isotopologues and solvates thereof are provided.
[0126] In one embodiment, the compound of formula (VI) is in a solid form. In one embodiment, the compound of formula (VI) is in a crystalline form. In one embodiment, the present disclosure provides a solid form comprising the compound of formula (VI). In one embodiment, the present disclosure provides a crystalline form comprising the compound of formula (VI).
[0127] In some embodiments, R 1 and R 2 are independently unsubstituted or substituted C 1-5 In some embodiments, R 1 and R 2 are independently unsubstituted or substituted linear C 1-5 In some embodiments, R 1 and R 2 are independently unsubstituted or substituted branched C 1-5 In some embodiments, R 1 and R 2 are independently unsubstituted linear C 1-5 In some embodiments, R 1 and R 2 are independently unsubstituted branched C 1-5 It is an alkyl.
[0128] In some embodiments, R 1 and R 2 are independently unsubstituted or substituted C 1-4 In some embodiments, R 1 and R 2 are independently unsubstituted or substituted linear C 1-4 In some embodiments, R 1 and R 2 are independently unsubstituted or substituted branched C 1-4In some embodiments, R 1 and R 2 are independently unsubstituted linear C 1-5 In some embodiments, R 1 and R 2 are independently unsubstituted branched C 1-4 It is an alkyl.
[0129] In some embodiments, R 1 and R 2 are independently unsubstituted or substituted C 1-3 In some embodiments, R 1 and R 2 are independently unsubstituted or substituted linear C 1-3 In some embodiments, R 1 and R 2 are independently unsubstituted or substituted branched C 1-3 In some embodiments, R 1 and R 2 are independently unsubstituted linear C 1-3 In some embodiments, R 1 and R 2 are independently unsubstituted branched C 1-3 It is an alkyl.
[0130] In some embodiments, R 1 and R 2 are independently unsubstituted or substituted C 1-2 In some embodiments, R 1 and R 2 are independently unsubstituted C 1-2 In some embodiments, R 1 and R 2 are independently substituted C 1-2 It is an alkyl.
[0131] In some embodiments, R 1 and R2 are independently unsubstituted or substituted C 1-2 In some embodiments, R 1 and R 2 are independently unsubstituted C 1-2 In some embodiments, R 1 and R 2 are independently substituted C 1-2 It is an alkyl.
[0132] In some embodiments, R 1 and R 2 is independently an unsubstituted or substituted methyl group. In some embodiments, R 1 and R 2 are independently a substituted methyl group. compound 6
[0133] The present specification provides compound 6, which has the following structure and is named (2R,2'R)-2,2'-(benzylazanediyl)bis(propan-1-ol). [ka]
[0134] In one embodiment, compound 6 is in a solid form. In one embodiment, compound 6 is in a crystalline form. In one embodiment, the present disclosure provides a solid form comprising compound 6. Form A
[0135] In certain embodiments, the present specification provides Form A of Compound 6, by way of example only and not by way of limitation.
[0136] In one embodiment, Form A is a solid form of Compound 6. In one embodiment, Form A is an anhydrous solid form of Compound 6. In another embodiment, Form A is crystalline. In another embodiment, Form A has an X-ray powder diffraction pattern comprising peaks at 2θ=about 22.5°, 27.1°, and 27.3°. In another embodiment, Form A has a melting point temperature of about 91° C. to about 93° C.
[0137] In certain embodiments, Form A provided herein is obtained by recrystallization experiments and anti-solvent recrystallization experiments. In certain embodiments, Form A is obtained from a specific solvent system, the solvent system comprising toluene, heptane, water, methanol, and mixtures thereof.
[0138] In one embodiment, the method of preparing Form A includes the steps of: 1) mixing compound 6 with a solvent (e.g., toluene) mixture containing n-heptane (e.g., at least about 75% by volume of n-heptane); 2) stirring at a constant temperature (e.g., about 0° C. to about 10° C., e.g., about 5° C.) for a period of time (e.g., about 1 hour to about 6 hours, e.g., about 3 hours); 3) collecting the solid and optionally drying it.
[0139] In one embodiment, the method of preparing Form A includes the steps of: 1) mixing compound 6 with a solvent (e.g., methanol) mixture containing n-heptane; 2) heating to a certain temperature (e.g., between about 0° C. and about 75° C., e.g., about 50° C.) and holding for a period of time (e.g., between about 1 hour and about 6 hours, e.g., about 3 hours); 3) cooling to a second temperature (e.g., between about 0° C. and about 50° C., e.g., about 25° C.); 4) collecting the solid and optionally drying.
[0140] In certain embodiments, the solid forms provided herein (e.g., Form A of Compound 6) are substantially crystalline, for example as indicated by X-ray powder diffraction measurements. In one embodiment, Form A has the X-ray powder diffraction pattern shown in Figure 5. In one embodiment, as shown in Figure 5, Form A has an X-ray powder diffraction pattern at 2θ=about 9.3°, 9.6°, 13.6°, 13.8°, 14.7°, 15.3°, 15.5°, 15.7°, 16.7°, 16.8°, 17.0°, 18.6°, 19.2°, 20.6°, 21.0°, 22.4°, 22.5°, 24.0°, 24.2°. , 25.3°, 25.9°, 26.4°, 27.1°, 27.3°, 28.4°, 28.7°, 29.3°, 29.9°, 30.1°, 31.0°, 31.5°, 34.1°, 34.8°, 35.4°, 37.1°, 37.7°, 38.2° or 39.0°. In certain embodiments, Form A has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 characteristic X-ray powder diffraction peaks at about 13.6, 13.8, 14.7, 15.3, 15.5, 21.0, 22.4, 22.5, 24.0, 24.2, 27.1, or 27.3 degrees 2θ. In other embodiments, Form A has 1, 2, 3, 4, 5, 6, 7, 8, or 9 characteristic X-ray powder diffraction peaks at about 14.7, 15.3, 15.5, 22.4, 22.5, 24.0, 24.2, 27.1, or 27.3 degrees 2θ. In another embodiment, Form A has one, two, three, four, five, or six characteristic X-ray powder diffraction peaks at about 15.3°, 22.4°, 22.5°, 24.2°, 27.1°, or 27.3° 2θ. In another embodiment, Form A has one, two, or three characteristic X-ray powder diffraction peaks at about 22.5°, 27.1°, or 27.3° 2θ.In another embodiment, Form A has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, or 38 characteristic X-ray powder diffraction peaks as set forth in Table 1.
[0141] In one embodiment, the present specification provides Form A having a DSC thermogram substantially as set forth in FIG. 6, wherein when heated from about 25° C. to about 150° C., the thermogram comprises an endothermic event with an onset temperature of about 91° C. and a peak temperature of about 92° C.
[0142] In one embodiment, the present specification provides Form A having a TGA thermogram substantially corresponding to the representative TGA thermogram set forth in Figure 7. In certain embodiments, when heated to about 20°C to about 300°C, the crystalline form exhibits a TGA thermogram that includes a total mass loss of 1% of the total mass of the sample between about 30°C and about 150°C. Thus, in certain embodiments, when heated to about ambient temperature to about 150°C, the crystalline form loses about 0.1% to about 5%, e.g., about 0.5% or about 3%, of its total mass.
[0143] In one embodiment, the present disclosure relates to a method for manufacturing a device substantially as set forth in FIG. 1 Form A with H NMR spectrum is provided.
[0144] In yet another embodiment, Form A is substantially pure. In certain embodiments, substantially pure Form A is substantially free of other solid forms, such as amorphous solids. In certain embodiments, the purity of substantially pure Form A is about 95% or more, about 96% or more, about 97% or more, about 98% or more, about 98.5% or more, about 99% or more, about 99.5% or more, or about 99.8% or more.
[0145] It should be noted that if there is a discrepancy between a structure as depicted and a name given to said structure, the structure as depicted shall bear more weight. EXAMPLES
[0146] Working Example Abbreviation The following examples are offered by way of illustration and not by way of limitation. The following abbreviations are used in the description and examples: [Table A] Synthesis Examples
[0147] The following synthetic examples are provided by way of illustration and not limitation to illustrate methods of preparing the compounds provided herein. Chemical structures were drawn and names for chemical structures were generated using Chemdraw 18.0.0.231 (Cambridgesoft, Perkin Elmer, Waltham, MA), published in 2018. Example 1: Synthesis of (3R,5R)-3,5-dimethylmorpholine hydrochloride [ka]
[0148] (R)-2-(benzylamino)propan-1-ol (2): To a 5 L 3-neck round bottom flask is added 2.0 L MeOH (10V), 200.0 g PhCHO (1.0 equiv), 162.8 g (R)-alaninol (1.15 equiv), and 237.6 g NaHCO3 (1.5 equiv) with stirring at 25-35° C. to form a suspension. Heating at reflux for 4 hours at an internal temperature of 62° C. is continued, after which the batch is cooled to 20-25° C. and filtered to remove undissolved solids, washing the filter cake with MeOH (1V).
[0149] Transfer the filtrate to a dry, clean 5 L 3-neck round bottom flask. Slowly add 39.2 g NaBH4 (0.55 equiv.) to the flask in small portions while controlling the internal temperature at 25°C-35°C (beware of foaming and exotherm). Stir the reaction mixture at 10-30°C for 16 hours.
[0150] After HPLC indicates completion of the reaction, the batch is quenched with NH4Cl (11.5 g in 11.5 mL water). The batch is stirred for 0.5 h and concentrated under vacuum to about 700 mL (about 3 V). The reaction mixture is exchanged with 500 mL MTBE (about 2 V). 1.2 L MTBE is added to the residue and the reaction mixture is stirred at 20-35°C for 0.5 h. The batch is filtered through a pad of diatomaceous earth and washed with 1.0 L MTBE. The filtrate is concentrated to dryness under vacuum.
[0151] 295.2 g of crude oily (R)-2-(benzylamino)propan-1-ol (2) was obtained, with an HPLC purity of 98.2%. 1 The 1 H NMR spectrum is shown in Figure 1.
[0152] N-benzyl-N-((R)-1-hydroxypropan-2-yl)-D-alaninic acid methyl ester (4) and (3R,5R)-4-benzyl-3,5-dimethylmorpholin-2-one (5):
[0153] In a 5 L 3-neck round bottom flask, 1.8 L of DCM, 216.3 g of (S)-(-)-methyl lactate (1.25 eq.) and 240.3 g of 2,6-lutidine (1.35 eq.) are added with stirring at 10°C to 30°C. The flask is evacuated and backfilled with nitrogen three times. The batch is cooled to -40°C to -20°C. 609.9 g of Tf2O (1.3 eq.) is added dropwise to the reaction mixture over 1.5 hours while controlling the temperature at -35°C to -25°C. The reaction mixture is then warmed to -5°C to 0°C and stirred for 1 hour. 600 mL of ice water is added to the reaction mixture and the reaction mixture is stirred at 0°C for 0.5 hours. At 0°C, the organic phase is separated and transferred to a 5 L 3-neck round bottom flask. Add 430.1 g of DIPEA (2.2 equiv.) to the flask at 0° C., followed by a solution of 295.2 g of crude (R)-2-(benzylamino)propan-1-ol (2) (1.0 equiv.) from the above process in 600 mL of DCM over 1 h at 0° C. Warm the reaction mixture to 10° C.-15° C. and stir for 16 h. Wash the reaction mixture with water (1 L × 3).
[0154] Separate the DCM phases, combine and concentrate to dryness under vacuum. Add 1.2 L of MTBE to the reaction mixture to dissolve the reaction mixture. Stir the reaction mixture at 10°C-20°C for 0.5 h and filter. Wash the filter cake with MTBE (400 mL). Combine the organic phases and concentrate to dryness under vacuum to obtain 463.2 g of crude product as a mixture (89.2%, a / a) of N-benzyl-N-((R)-1-hydroxypropan-2-yl)-D-alaninic acid methyl ester (4) (55.1%, a / a) and (3R,5R)-4-benzyl-3,5-dimethylmorpholin-2-one (5) (34.1%, a / a).
[0155] (2R,2'R)-2,2'-(benzylazanediyl)bis(propan-1-ol) (6):
[0156] In a 5 L 3-neck round bottom flask, add 2.3 L of MeOH and 463.2 g of a mixture of N-benzyl-N-((R)-1-hydroxypropan-2-yl)-D-alaninic acid methyl ester (4) and (3R,5R)-4-benzyl-3,5-dimethylmorpholin-2-one (5) (1.0 equiv.). To the reaction mixture, add 146.6 g of NaBH4 (2.0 equiv.) in portions at 20-30°C. Stir the reaction mixture for an additional 16 h.
[0157] Aqueous NH4Cl (40 g in 200 mL of HO) is added to the mixture to quench the reaction. The reaction mixture is concentrated under vacuum to remove most of the MeOH and exchanged with 1 L of n-heptane, then wet-triturated with 1.0 L of water and 2.0 L of n-heptane.
[0158] The reaction mixture is filtered. The filter cake is washed with n-heptane (500 mL), collected and dried in vacuum at 50° C.
[0159] 257.0 g of yellow solid (2R,2'R)-2,2'-(benzylazanediyl)bis(propan-1-ol) (6) was obtained, with a three-step yield of about 61%. The solid had a chemical purity of 97.3% and a dr of 99.3:0.7. 1 The H NMR spectrum is shown in FIG.
[0160] As an unexpected result, (2R,2'R)-2,2'-(benzylazanediyl)bis(propan-1-ol) (6) is a crystalline solid and has been identified as Form A. Furthermore, as an unexpected result, (2R,2'R)-2,2'-(benzylazanediyl)bis(propan-1-ol) (6) selectively crystallizes from the reaction mixture under the disclosed conditions. This method removes the undesired diastereomer and other by-products. Furthermore, this method produces the desired diastereomer with a high dr.
[0161] Process for improving the dr of (2R,2'R)-2,2'-(benzylazanediyl)bis(propan-1-ol) (6):
[0162] In a 1 L three-necked round bottom flask, add 127 mL (2V) of toluene, 635 mL of n-heptane (10V) and 63.5 g of (2R,2'R)-2,2'-(benzylazanediyl)bis(propan-1-ol) (6) (1.0 equiv., dr:99.4:0.6). The reaction mixture is stirred at 100 °C to form a clear solution and then stirred at 100 °C for an additional hour. The reaction mixture is cooled to 5 °C over 2 hours and stirred for an additional hour. The reaction mixture is filtered. The collected solid is washed with 127 mL (2V) of n-heptane and dried in vacuum at 50 °C.
[0163] 59.5 g of (2R,2'R)-2,2'-(benzylazanediyl)bis(propan-1-ol) (6) was obtained as a yellow solid, with a yield of about 93%. The solid obtained was also identified as Form A, with a chemical purity of 98.4% and a dr >98.5:1.5.
[0164] (3R,5R)-4-benzyl-3,5-dimethylmorpholine (7):
[0165] To a 500 mL clean and dry 3-neck flask at 20°C-35°C, add 180 mL of TfOH (3.0V) and 58.5 g of (2R,2'R)-2,2'-(benzylazanediyl)bis(propan-1-ol) (6) (1.0 equiv., dr :>98.5:1.5) in small portions with stirring. Stir the reaction mixture at 80°C for 16 h, then cool to 20°C-30°C. Add 20% aqueous NaOH (500 g) slowly dropwise with stirring to the reaction mixture at 0°C-10°C (ensuring pH>12). Extract the reaction mixture with MTBE (250 mL x 2). Combine the MTBE phases and filter. Concentrate the filtrate under vacuum.
[0166] 51.2 g of oily (3R,5R)-4-benzyl-3,5-dimethylmorpholine (7) was obtained with a yield of 89%, purity of 99.6%, ee>99.0%, dr>98.5:1.5, and the resulting material had the following properties as shown in FIG.1 The H NMR spectrum is shown.
[0167] (3R,5R)-3,5-Dimethylmorpholine hydrochloride (8):
[0168] Into a clean, dry 500 mL 3-neck flask, add 255 mL of MeOH (5V), 51.0 g of (3R,5R)-4-benzyl-3,5-dimethylmorpholine (7) (1.0 equiv.) and 3.6 g of Pd(OH)2 / C (7% wt. vs. compound 7, 0.5 mol% Pd, 65% water content, Kaili Catalyst Co.). Degas the autoclave and refill with hydrogen three times. Stir the reaction mixture for 16 h at 35°C-40°C under 1 atm of hydrogen. Filter the reaction mixture under nitrogen. Wash the collected solid with 100 mL of MeOH. Add 100 mL of HCl (4 M in 1,4-dioxane) to the filtrate to pH<3. Stir the reaction mixture for 1 h, concentrate under vacuum, then exchange with isopropanol (150 mL × 2). The reaction mixture is stirred with 51 mL of isopropanol (1V) and 102 mL of n-heptane (2V) for 16 h. The reaction mixture is filtered. The collected solid is washed with 51 mL of n-heptane and dried in a vacuum oven at 50° C. for 16 h.
[0169] 32.4 g of solid (3R,5R)-3,5-dimethylmorpholine hydrochloride (8) was obtained with a yield of 86%. The solid obtained is shown in FIG. 1 The H NMR spectrum is shown. Form A
[0170] Form A is an anhydrous crystalline solid form of Compound 6. This form can be obtained by recrystallization from a mixture of toluene and n-heptane or a mixture of methanol and n-heptane.
[0171] Form A has a crystalline XRPD pattern as shown in Figure 5. The TGA and DSC thermograms of Form A are shown in Figures 6 and 7, respectively. The DSC thermogram shows only a major event corresponding to melting / decomposition with an onset temperature of 91.2°C and a peak temperature of 92.3°C. By 150°C, a TGA weight loss of 1% was observed.
[0172] Figure 5 provides the XRPD pattern of Form A. The X-ray diffraction peaks for Form A are listed in Table 1 below.
[0173] [Table 1]
[0174] The conditions for measuring the XRPD patterns are shown in Table 2 below.
[0175] [Table 2]
[0176] A number of references have been cited, the disclosures of which are incorporated herein by reference in their entireties.
Claims
1. A compound of formula (VI), [C25] or a pharma- ceutically acceptable salt, solid form, enantiomer, isotope or solvate thereof, Where: R 1 and R 2 are independently unsubstituted or substituted C 1-5 A compound that is an alkyl.
2. R 1 and R 2 are independently unsubstituted or substituted C 1-4 The compound of claim 1 , wherein the aryl group is an alkyl group.
3. R 1 and R 2 are independently unsubstituted linear C 1-4 The compound of claim 1 , wherein the aryl group is an alkyl group.
4. R 1 and R 2 are independently unsubstituted branched C 1-4 The compound of claim 1 , wherein the aryl group is an alkyl group.
5. R 1 and R 2 The compound of claim 1 , wherein is a methyl group.
6. A solid form comprising a compound according to any one of claims 1 to 5.
7. The compound according to claim 5, A crystalline form having an X-ray powder diffraction pattern containing one, two or three peaks at 2θ=22.5°, 27.1° or 27.3°±0.2°.
8. 8. The crystalline form of claim 7, wherein the X-ray powder diffraction pattern further comprises one, two or three peaks at 2θ=15.3°, 22.4° or 24.2±0.2°.
9. 9. The crystalline form of claim 7 or 8, wherein the crystalline form has a melting point temperature of about 91°C to about 93°C.
10. 10. The crystalline form of any one of claims 7 to 9, wherein the crystalline form is anhydrous.
11. A compound of formula (VIII), [C26] or a pharma- ceutically acceptable salt, solid form, enantiomer, isotope or solvate thereof, comprising the steps of: The method comprises reacting a compound of formula (VII) [C27] of, In the presence of a catalyst, hydrogen (H 2 ), Where: R 1 and R 2 are independently unsubstituted or substituted C 1-5 The method is alkyl.
12. The method of claim 11 , wherein the solvent is methanol, ethanol or isopropanol.
13. The catalyst is Pd(OH). 2 13. The method according to claim 11 or 12, wherein the Pd / C or Pd / C is
14. The hydrogen (H 2 14. The method of any one of claims 11 to 13, wherein the pressure of (a) is from about 1 to about 10 atm and the contacting is conducted at a temperature of from about 25°C to about 55°C.
15. The hydrogen (H 2 15. The method of claim 14, wherein the pressure of
16. The hydrogen (H 2 15. The method of claim 14, wherein the pressure of (a) is about 1 to about 3 atm.
17. The compound of formula (VII) is a compound of formula (VI) [C28] of, The method of any one of claims 11 to 16, wherein the compound is prepared by contacting with an acid.
18. 18. The method of claim 17, wherein the acid is TfOH and the contacting is carried out at a temperature of from about 20° C. to about 140° C.
19. The compound of formula (VI) is a compound of formula (IV) [C29] and, Compound of formula (V) [C30] 19. The method of claim 17 or 18, wherein the compound is prepared by contacting a mixture of
20. The reducing agent is NaBH 4 20. The method of claim 19, wherein said contacting is carried out in a solvent selected from the group consisting of methanol, ethanol, isopropanol, and mixtures thereof at a temperature of from about 15° C. to about 35° C.
21. The method according to any one of claims 17 to 20, wherein the compound of formula (VI) is in solid form.
22. R 1 and R 2 The method according to any one of claims 17 to 20, wherein is a methyl group.
23. 23. The method of claim 22, wherein the compound of formula (VI) comprises a crystalline form of the compound of formula (VI), the crystalline form having an X-ray powder diffraction pattern comprising one, two or three peaks at 2θ=22.5°, 27.1° or 27.3°±0.2°.
24. 24. The method of claim 23, wherein the X-ray powder diffraction pattern further comprises one, two or three peaks at 2θ=15.3°, 22.4° or 24.2°±0.2°.
25. 25. The method of claim 23 or 24, wherein the crystalline form has a melting point temperature of about 91°C to about 93°C.
26. The crystalline form of any one of claims 23 to 25, which is anhydrous.
27. The mixture of the compound of formula (IV) and the compound of formula (V) is a compound of formula (II) [C31] of, Compound of formula (III) [C32] and, The method of any one of claims 11 to 26, wherein the compound is prepared by contacting in the presence of a suitable base in a suitable solvent.
28. 28. The method of claim 27, wherein said suitable base is 2,6-lutidine, said suitable solvent is dichloromethane, and said contacting is performed at a temperature from about 0° C. to about 40° C.
29. The compound of formula (II) is a compound of formula (I) [C33] of, 29. The method of claim 27 or 28, wherein the compound is prepared by contacting PhCHO in the presence of a suitable base in a suitable solvent.
30. The suitable base is NaHCO 3 30. The method of claim 29, wherein the suitable solvent is methanol and the contacting is carried out at a temperature of about 20° C. to about 40° C.
